Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device

NCT02119247 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DEVICE: CHF 6001 dry powder for inhalation via NEXThaler®
DEVICE: CHF 6001 DPI capsules for inhalation via Aerolizer

Sponsor

Chiesi Farmaceutici S.p.A.